Author

E. Cameroni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 10 Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 14 Research Focus:host-pathogen & immune response· 12 Organism:human· 11 Assay:proteomics· 8 Research Focus:cell type annotation· 4 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:differential expression· 2

Frequent Co-Authors

A. Telenti· 10 shared D. Pinto· 10 shared K. Culap· 10 shared J. E. Bowen· 9 shared A. C. Walls· 8 shared D. Corti· 8 shared H. W. Virgin· 8 shared N. Czudnochowski· 8 shared

Activity by Year

2020-2023 · peak 8/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersImmunology

A. Telenti

Mutual co-authors in cluster

Author profile →

14 papers

Recent·Most cited

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

bioRxiv · Sep 30, 2022Immunology

The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice

F. A. Lempp, T. Volz, E. Cameroni, F. Benigni, J. Zhou, L. E. Rosen, J. Noack, F. Zatta, H. Kaiser, S. Bianchi, G. Lombardo, S. Jaconi, H. Imam, L. B. Soriaga, N. Passini, , M. A. Schmid

This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.

bioRxiv · Sep 9, 2022Microbiology

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines

J. E. Bowen, K. R. Sprouse, A. C. Walls, I. G. Mazzitelli, J. K. Logue, N. M. Franko, K. Ahmed, A. Shariq, E. Cameroni, A. Gori, A. Bori, C. M. Posavad, J. M. Dan, Z. Zhang, D. Weiskopf, , D. Veesler

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

bioRxiv · Mar 15, 2022 · PreprintImmunology

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

bioRxiv · Dec 12, 2021Immunology

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

bioRxiv · May 9, 2021 · PreprintImmunology

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody

M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 7, 2021 · PreprintImmunology

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, , Veesler

This study identifies antibodies against SARS-CoV-2 that balance neutralization potency and breadth, with some showing high resistance to viral escape.

bioRxiv · Apr 6, 2021 · PreprintMicrobiology

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

F. A. Lempp, L. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, Y.-J. Park, S. Bianchi, A. C. Walls, J. E. Bowen, J. Zhou, H. Kaiser, M. Agostini, M. Meury, E. Dellota, S. Jaconi, , D. Corti

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

bioRxiv · Apr 3, 2021 · PreprintMicrobiology

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

bioRxiv · Mar 31, 2021 · PreprintImmunology

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

A. L. Cathcart, C. Havenar-Daughton, F. A. Lempp, D. Ma, M. Schmid, M. L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, , C. M. Hebner

This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.

bioRxiv · Mar 9, 2021 · PreprintImmunology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

bioRxiv · Jan 14, 2021Immunology

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols

The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.

bioRxiv · Nov 4, 2020Microbiology

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

bioRxiv · Apr 7, 2020Immunology